D.E. Shaw & Co’s scPharmaceuticals SCPH Stock Holding History

D.E. Shaw & Co’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-43,935	Closed	-$545K	–	3870
2018 Q1	$545K	Buy	+43,935	New	+$590K	﹤0.01%	2837

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

D.E. Shaw & Co's SCPH Position: Q2 2018 in Review

D.E. Shaw & Co sold out of scPharmaceuticals (SCPH) in Q2 2018, closing a stake of 43,935 shares — an estimated $545K sold.

D.E. Shaw & Co first reported a position in SCPH in Q1 2018 and held it in 1 quarter. The position peaked at $545K in Q1 2018. 41 funds tracked by Wall St. Rank hold SCPH as of Q2 2018.

D.E. Shaw & Co reported no remaining scPharmaceuticals position as of Q2 2018 after selling out during the quarter.
D.E. Shaw & Co sold 43,935 scPharmaceuticals shares in Q2 2018, an estimated $545K.
D.E. Shaw & Co first reported a position in scPharmaceuticals in Q1 2018 and held it in 1 quarter.
D.E. Shaw & Co's scPharmaceuticals position peaked at $545K in Q1 2018.
41 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2018.

Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.